GENOME-WIDE INTEGRATION OF ALZHEIMER’S DISEASE GENETICS AND MYELOID CELL GENOMICS IDENTIFIES NOVEL RISK GENES EXPRESSED IN MICROGLIA

Edoardo Marcora,Manav Kapoor,Gloriia Novikova,Alan E. Renton,Ke Hao,Alison Goate

DOI: https://doi.org/10.1016/j.jalz.2019.08.038

2019-01-01

Abstract:In recent years, large-scale and hypothesis-free genetic studies have identified ∼30 genomic regions that pass the genome-wide significance threshold for association with Alzheimer's disease (AD). These risk loci contain hundreds of genes and, since the vast majority of risk variants in these regions are non-coding, it is difficult to identify the causal genes with confidence. Indeed, compelling evidence of causal association exists only for a handful of genes where functional coding risk variants have been identified (e.g., APOE, TREM2, and ABCA7), the majority of which are expressed and execute key functions in microglia. Here we apply our previous findings that AD heritability is enriched in enhancer elements active in peripheral blood or brain myeloid cells (microglia) by performing a genome-wide and hypothesis-driven functional genomic scan that integrates Alzheimer's disease genetics and myeloid cell genomics (eQTL and epigenomic datasets) to discover novel microglial risk genes. We were able to nominate several candidate causal genes in known genome-wide significant loci, as well as novel genes in loci that are only suggestively associated with AD in standard GWAS analysis but are study-wide significant in our integrative analysis. In addition, we were able to predict how modulation of these genes expression would affect disease risk. Integration of AD genetics data with eQTL and epigenomic datasets obtained from disease-relevant cell types enables the discovery of AD risk genes and how to modulate their activity for disease risk reduction, which is critical for the formulation of novel therapeutic hypotheses for AD.